How migraine science has changed

For most of the 20th century, migraine was explained as a vascular problem — a story about blood vessels dilating and constricting inside the skull. That story shaped treatment (and stigma) for generations.

It turned out to be incomplete.

The shift to a neurological model

Over the past 30 years, migraine has been reframed as fundamentally a neurological condition. Blood vessels are involved, but they aren’t the driver. The driver is a hyper-responsive brain — one that reacts to sensory, hormonal, and metabolic input more strongly than a non-migraine brain does.

Two key concepts have emerged:

• Cortical spreading depression — the slow wave of altered electrical activity that appears to underlie aura and may be involved in attack initiation more broadly.
• The trigeminovascular system — the network of nerves and vessels around the brain that, when activated, produces the pain of an attack and its accompanying nausea, sensitivity, and inflammation.

CGRP — the molecule that changed treatment

In the 1980s, researchers identified a peptide called CGRP (calcitonin gene-related peptide) that is released during migraine attacks and appears to drive much of the pain and inflammation.

For decades this was interesting basic science. In the 2010s, it became a treatment revolution:

• CGRP monoclonal antibodies — injected once a month (or less), block CGRP or its receptor. Approved from 2018 onward. Many people who had failed multiple older preventives had substantial improvement.
• Gepants — small-molecule CGRP blockers taken as pills, both for acute treatment and prevention.
• Ditans — a newer acute class that works differently from triptans, useful for people who can’t take triptans for cardiovascular reasons.

For the first time in migraine history, there are preventive treatments designed for migraine rather than borrowed from other conditions.

What is still unclear

• Why some people develop migraine and others don’t. Genetics play a role but don’t tell the whole story.
• Why some attacks respond to a given treatment and others don’t.
• Why chronic migraine develops in some people and not others.
• Whether we can eventually prevent migraine from becoming chronic in the first place.

Where the field is heading

• Personalized treatment. Matching individuals to treatments based on their attack pattern, aura status, and biomarkers.
• Neuromodulation devices — non-invasive stimulators that alter nerve activity, for people who prefer or need drug-free options.
• Better understanding of the postdrome and premonitory phases — the parts of the attack we have historically neglected.
• Migraine and mental health — recognizing bidirectional links with depression, anxiety, and trauma, and treating them together.

The last decade has been the most productive in migraine research in a century. If you are new to the diagnosis, or if you were told years ago that “nothing more can be done,” it is genuinely worth talking to a headache specialist about what has changed.